LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

Inicio・Lista de Acciones・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Cerrado

SectorSanidad

24.72 1.69

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

23.97

Máximo

25.07

Métricas clave
By Trading Economics
Ingresos	-10M -67M
Margen de beneficios	-7,753.425
Empleados	186
EBITDA	-9.8M -73M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+91.14% upside

Dividendos
By Dow Jones
Próximas Ganancias	25 feb 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	111M 1.6B
Apertura anterior	23.03
Cierre anterior	24.72

Noticias sobre sentimiento de mercado

By Acuity

50%

161 / 351 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

18.91 / 20.63 Soporte y Resistencia

Celldex Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

24 feb 2026, 23:07 UTC

Ganancias

Woolworths 1st Half Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24 feb 2026, 23:01 UTC

Ganancias

Fortescue 1st Half Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24 feb 2026, 22:59 UTC

Ganancias

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability -- Update

24 feb 2026, 22:42 UTC

Ganancias

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability

24 feb 2026, 22:24 UTC

Adquisiciones, fusiones, absorciones

Warner Bros. Discovery Board Says Paramount Skydance's New Proposal Could Top Netflix Agreement -- Update

24 feb 2026, 23:46 UTC

Charlas de Mercado

Gold Edges Higher Amid Possible Position Adjustments -- Market Talk

24 feb 2026, 23:36 UTC

Charlas de Mercado

Nikkei May Rise, Tracking Wall Street's Rebound -- Market Talk

24 feb 2026, 23:30 UTC

Charlas de Mercado

Fortescue's Copper Bet Is Long Term, While Iron Ore Remains Near-Term Driver -- Market Talk

24 feb 2026, 23:20 UTC

Charlas de Mercado

Fortescue Dividend Beat Overshadows Profit Miss -- Market Talk

24 feb 2026, 23:20 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

24 feb 2026, 23:16 UTC

Ganancias

Oversea-Chinese Banking Corp.'s CEO: "Looking Ahead, We Remain Cautious Yet Positive">O39.SG

24 feb 2026, 23:13 UTC

Ganancias

Oversea-Chinese Banking Corp. FY25 Non-Interest Income S$5.46B Vs. S$4.72B >O39.SG

24 feb 2026, 23:12 UTC

Ganancias

Oversea-Chinese Banking Corp.: FY25 Net Interest Income S$9.15B Vs. S$9.76B>O39.SG

24 feb 2026, 23:10 UTC

Ganancias

Oversea-Chinese Banking Corp. FY25 NPL Ratio 0.9%, Unchanged on Year>O39.SG

24 feb 2026, 23:10 UTC

Ganancias

Oversea-Chinese Banking Corp. FY25 Net Interest Margin 1.91%, Down 29bps on Year>O39.SG

24 feb 2026, 23:08 UTC

Ganancias

Oversea-Chinese Banking Corp. FY25 Net S$7.42B Vs. Net S$7.59B >O39.SG

24 feb 2026, 23:07 UTC

Ganancias

Oversea-Chinese Banking Corp. FY25 Total Income S$14.61B Vs. S$14.47B>O39.SG

24 feb 2026, 22:52 UTC

Ganancias

Woolworths 1H Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24 feb 2026, 22:46 UTC

Ganancias

Fortescue 1H Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24 feb 2026, 22:31 UTC

Adquisiciones, fusiones, absorciones

Warner Receives New Bid From Paramount -- 3rd Update

24 feb 2026, 22:29 UTC

Ganancias

Woolworths: FY Ebit Growth for Australian Food Expected at Upper End of Mid-to-High Single Digit Range Provided in August

24 feb 2026, 22:28 UTC

Ganancias

Woolworths: Australian Food Current Growth Rates Reflect Some Benefit from Cycling of Industrial Action Impacts

24 feb 2026, 22:27 UTC

Ganancias

Woolworths: Australian Food Sales +7.2% Excluding Tobacco in 2H First Seven Weeks

24 feb 2026, 22:27 UTC

Ganancias

Woolworths: Australian Food Sales +5.8% in 2H First Seven Weeks

24 feb 2026, 22:25 UTC

Ganancias

Woolworths: Customers Continue to be Value-Focused, Shopping Multiple Retailers in Highly Competitive Environment

24 feb 2026, 22:24 UTC

Ganancias

Woolworths: Trading in 3Q to Date Has Been Strong in Australian Food

24 feb 2026, 22:23 UTC

Ganancias

Woolworths 1H Group Sales A$37.1 Bln, Up 3.4%

24 feb 2026, 22:22 UTC

Ganancias

Woolworths Interim Dividend 45 Australian Cents/Share

24 feb 2026, 22:22 UTC

Ganancias

Woolworths 1H Profit Before Significant Items A$859 Mln, Up 16.4%

24 feb 2026, 22:21 UTC

Ganancias

Woolworths 1H Statutory Net Profit A$374 Mln, Down 49.4%

Comparación entre iguales

Cambio de precio

Celldex Therapeutics Inc previsión

Precio Objetivo

By TipRanks

91.14% repunte

Estimación a 12 Meses

Media 44 USD 91.14%

Máximo 62 USD

Mínimo 24 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Celldex Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

4 ratings

Comprar

Mantener

Vender

De acuerdo con 4 analistas que ofrecen calificaciones bursátiles a para Celldex Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

18.91 / 20.63Soporte y Resistencia

Recent bullish events outweigh bearish events.

All events are bearish.

Sentimiento

By Acuity

161 / 351 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.